These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8166524)

  • 21. Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass.
    Kagisaki K; Masai T; Kadoba K; Sawa Y; Nomura F; Fukushima N; Ichikawa H; Ohata T; Suzuki K; Taketani S; Matsuda H
    Artif Organs; 1997 Jul; 21(7):836-40. PubMed ID: 9212969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit?
    Mahmood S; Bilal H; Zaman M; Tang A
    Interact Cardiovasc Thorac Surg; 2012 Apr; 14(4):406-14. PubMed ID: 22228288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective effect of heparin-coated circuits on the platelets during cardiopulmonary bypass.
    Zhang K; Hu Z; Yang Y; Huang R; Fan H; Sun Z
    J Huazhong Univ Sci Technolog Med Sci; 2003; 23(4):403-6. PubMed ID: 15015647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients.
    Despotis GJ; Filos KS; Zoys TN; Hogue CW; Spitznagel E; Lappas DG
    Anesth Analg; 1996 Jan; 82(1):13-21. PubMed ID: 8712388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of heparin bonding on pediatric cardiopulmonary bypass: a prospective randomized study.
    Grossi EA; Kallenbach K; Chau S; Derivaux CC; Aguinaga MG; Steinberg BM; Kim D; Iyer S; Tayyarah M; Artman M; Galloway AC; Colvin SB
    Ann Thorac Surg; 2000 Jul; 70(1):191-6. PubMed ID: 10921707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The evaluation of the bio-compatibility and the clinical usefulness of heparin-coated cardiopulmonary bypass circuits].
    Yamanaka J; Takeuchi Y; Torii S; Gomi A; Nakatani H; Kohno K
    Nihon Kyobu Geka Gakkai Zasshi; 1996 Jan; 44(1):47-53. PubMed ID: 8683171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery.
    Hoel TN; Videm V; Baksaas ST; Mollnes TE; Brosstad F; Svennevig JL
    Perfusion; 2004 May; 19(3):177-84. PubMed ID: 15298426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement activation during cardiopulmonary bypass: effects of immobilized heparin.
    Pekna M; Hagman L; Haldén E; Nilsson UR; Nilsson B; Thelin S
    Ann Thorac Surg; 1994 Aug; 58(2):421-4. PubMed ID: 8067842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparin-coated cardiopulmonary bypass circuit: clinical effects in pediatric cardiac surgery.
    Miyaji K; Hannan RL; Ojito J; Jacobs JP; White JA; Burke RP
    J Card Surg; 2000; 15(3):194-8. PubMed ID: 11414605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation.
    Kuitunen AH; Heikkilä LJ; Salmenperä MT
    Ann Thorac Surg; 1997 Feb; 63(2):438-44. PubMed ID: 9033316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar clinical results and minor biochemical differences.
    Wimmer-Greinecker G; Matheis G; Martens S; Oremek G; Abdel-Rahman U; Moritz A
    Eur J Cardiothorac Surg; 1999 Aug; 16(2):211-7. PubMed ID: 10485423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
    Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C
    J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
    Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
    J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are any biocompatible coatings capable of attenuating the deleterious effects of cardiopulmonary bypass?
    Marcoux JE; Mycyk TR
    Perfusion; 2013 Sep; 28(5):433-9. PubMed ID: 23630197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
    Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
    J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Release of proinflammatory cytokines during pediatric cardiopulmonary bypass: heparin-bonded versus nonbonded oxygenators.
    Ashraf S; Tian Y; Cowan D; Entress A; Martin PG; Watterson KG
    Ann Thorac Surg; 1997 Dec; 64(6):1790-4. PubMed ID: 9436574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
    Bagge L; Borowiec JW; Thelin S; Hultman J
    Scand Cardiovasc J; 1997; 31(5):275-81. PubMed ID: 9406294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits.
    Olsson C; Siegbahn A; Haldén E; Nilsson B; Venge P; Thelin S
    Ann Thorac Surg; 2000 Mar; 69(3):743-9. PubMed ID: 10750754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of three oxygenator-coated and one total-circuit-coated extracorporeal devices.
    Baksaas ST; Videm V; Pedersen T; Karlsen H; Mollnes TE; Brosstad F; Svennevig JL
    Perfusion; 1999 Mar; 14(2):119-27. PubMed ID: 10338323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.